Celltrion gets EU positive opinion on subcutaneous biosimilar
Celltrion receives EMA CHMP positive opinion on its application for marketing authorization of a subcutaneous version of its Remsima biosimilar.
Archives for September 24, 2019
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs